MedTrace Logo

An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron

NCT00868764 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-07-24

No results posted yet for this study

Summary

This study aims to evaluate the effect of age and BMI on the pharmacokinetics and safety of Sancuso®.

Conditions

  • Pharmacokinetics

Interventions

DRUG

granisetron

3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days

Sponsors & Collaborators

  • Kyowa Kirin Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Stuart J Mair · Syneos Health

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00868764 on ClinicalTrials.gov